CSRxP spokesman Will Holley released the following statement applauding the Trump Administration’s focus on out-of-control drug prices on the 100th day since the release of the Blueprint to Lower Drug Prices:
“We applaud the Administration’s focus on out-of-control drug prices. While we do not see eye-to-eye on each of the policies that have been put forward over the last 100 days, the Administration deserves credit for its efforts to address this critical issue.
“We continue to believe, however, that the fundamental problem is the price that is set by drug manufacturers alone. Reforms that will have a lasting, structural impact on drug prices must address the incentives that drive list and launch prices ever higher, and the anticompetitive tactics that brand-name drug manufacturers use to artificially extend their monopoly pricing power.
“We will continue to work with the Administration, Congress, and other stakeholders to achieve our shared goal of affordable prescription drugs for all Americans who depend on them.”